Free Trial
Adam Vogel

Adam Vogel Analyst Performance

Senior Analyst Equity Research | Biotechnology at Craig Hallum

Adam Vogel is a stock analyst at Craig Hallum focused in the medical sector, covering 5 publicly traded companies. Over the past year, Adam Vogel has issued 10 stock ratings, including strong buy and buy recommendations. While full access to Adam Vogel's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Adam Vogel's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 0 Years
Buy Recommendations
100.00% 10 Buy Ratings
Companies Covered
5 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy10.0%1 ratings
Buy90.0%9 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 10 total stock ratings issued by Adam Vogel at Craig Hallum, the majority (90.0%) have been Buy recommendations, followed by 10.0% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
5 companies

Adam Vogel, an analyst at Craig Hallum, currently covers 5 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
80.0%
Manufacturing
1 company
20.0%

Adam Vogel of Craig Hallum specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
60.0%
Miscellaneous
1 company
20.0%
MED - DRUGS
1 company
20.0%

Adam Vogel's Ratings History at Craig Hallum

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
LB Pharmaceuticals Inc stock logo
LBRX
LB Pharmaceuticals
4/10/2026Initiated Coverage$26.29$36.00Buy
Immunome, Inc. stock logo
IMNM
Immunome
3/4/2026Boost Price Target$22.52$36.00Buy
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
1/30/2026Initiated Coverage$3.43$10.00Buy
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
1/30/2026Upgrade$3.61Strong-Buy
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
1/7/2026Reiterated Rating$77.97$116.00Buy
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
12/3/2025Initiated Coverage$8.94$15.00Buy
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
12/3/2025Initiated Coverage$9.82Buy
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
11/3/2025Initiated Coverage$56.59$109.00Buy
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
11/3/2025Initiated Coverage$53.90$109.00Buy
Immunome, Inc. stock logo
IMNM
Immunome
9/5/2025Initiated Coverage$9.80$26.00Buy